Press coverage about Haemonetics Corporation (NYSE:HAE) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Haemonetics Corporation earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.3347227006403 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of brokerages have recently commented on HAE. Zacks Investment Research lowered shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, August 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Haemonetics Corporation currently has a consensus rating of “Hold” and a consensus price target of $41.67.
Shares of Haemonetics Corporation (NYSE HAE) opened at 43.03 on Friday. The company has a market cap of $2.26 billion, a PE ratio of 558.83 and a beta of 0.89. The company has a 50-day moving average of $42.17 and a 200-day moving average of $40.91. Haemonetics Corporation has a 1-year low of $32.76 and a 1-year high of $43.77.
Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same quarter in the previous year, the company earned $0.25 EPS. The business’s revenue was up .5% on a year-over-year basis. Equities analysts forecast that Haemonetics Corporation will post $1.60 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Haemonetics Corporation (HAE) Receives Daily Coverage Optimism Rating of 0.01” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/09/23/haemonetics-corporation-hae-receives-daily-coverage-optimism-rating-of-0-01.html.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.